Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold
Ask for high quality link by putting your email below
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
The extracellular matrix (ECM) is known as a molecular network of macromolecules present in all solid tissues (Figure 1), which plays an important role in the growth, migration and differentiation of cells. This ECM is Read more…
We were invited at the workshop organized by SMILL-E (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer) and Yncrea during MedFit event last week. This great workshop was about Digital and Micro Read more…
Atopic dermatitis (AD) is a chronic, common inflammatory skin disease affecting 15-20% of children and 1-3% of adults worldwide. Loss of bacterial diversity from excess abundance of Staphylococcus aureus is associated with increased disease severity, Read more…
1 Comment
SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm
[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]